A proof-of Concept Study of the Use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the Treatment of COVID-19-related Pneumonia
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Baricitinib (Primary)
- Indications COVID-19 pneumonia
- Focus Proof of concept; Therapeutic Use
- Acronyms BREATH
Most Recent Events
- 26 Aug 2022 Status changed from recruiting to discontinued.
- 12 Aug 2020 Status changed from not yet recruiting to recruiting.
- 26 May 2020 New trial record